The US FDA expanded the use of FoundationOne Liquid CDx as a companion diagnostic for certain prostate cancer patients eligible for treatment with olaparib.

The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.

Lilly’s diabetes and oncology franchises epitomize the effects of the pandemic on pharmaceutical sales. For much smaller companies, these effects were magnified.

PD-1/PDL-1 inhibitors have not proved effective for ovarian cancer on their own or in combinations. Now Roche's Tecentriq, combined with the firm's blockbuster Avastin, has suffered a similar fate to Merck KGaA and Pfizer's Bavencio in failing to improve survival.